Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.
about
Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation TherapyMultidrug Resistance Proteins (MRPs) and Cancer TherapyChromobox homolog 2 protein: A novel biomarker for predicting prognosis and Taxol sensitivity in patients with breast cancer.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceSynthesis and biological evaluation of pentacyclic strychnos alkaloids as selective modulators of the ABCC10 (MRP7) efflux pumpIn vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1.The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.Development and qualification of an LC-MS/MS method for investigating the biological implications of micelle entrapped paclitaxel in cell culture and rats.IKK inhibition increases bortezomib effectiveness in ovarian cancer.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.2-Trifluoromethyl-2-Hydroxypropionamide Derivatives as Novel Reversal Agents of ABCG2 (BCRP)-Mediated Multidrug Resistance: Synthesis and Biological Evaluations.Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
P2860
Q26775004-D4C87E6B-8E29-4E18-B0E7-E4C9F040BAEFQ26992204-141628CC-CCE6-4837-843A-6F48832E6F73Q33597544-FD23B509-6D62-4C21-9C37-AA629918351EQ34774854-EAECB65E-79F9-4115-A67D-871F88E5A2AFQ34796487-207A3143-E1F4-4068-B15E-204A74EEFDD1Q34914312-60AE17C9-213F-4C9E-8954-FB683951A7EBQ35238509-86FE4E8B-A7D0-4990-9FCC-E47F55C2B47FQ36121125-BA1C87EC-8082-4040-9EBC-C24EFFB0753DQ36282159-C55FDC83-F7E0-4E27-ADDE-594994D8D177Q36413454-6B8924F0-4AC5-4AE0-A84F-4289F68BAC5AQ38246305-F30DD9BD-1399-469B-ABEE-0D2962FF84C0Q38707907-895B7207-2C01-4539-8F07-3B2FA36EEFBCQ49888021-DAE127FF-3860-4205-B45E-1EE2D9B3248FQ50113702-CF84B9C0-5B47-4807-8694-DDC7708D61D1Q51170112-FF125370-3730-48D2-8C20-0C4731226C50Q52862916-ABEDD822-ACC1-4CF1-A2FF-FB5E10BB9D0D
P2860
Masitinib antagonizes ATP-binding cassette subfamily C member 10-mediated paclitaxel resistance: a preclinical study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@en
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@nl
type
label
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@en
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@nl
prefLabel
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@en
Masitinib antagonizes ATP-bind ...... sistance: a preclinical study.
@nl
P2093
P2860
P1476
Masitinib antagonizes ATP-bind ...... esistance: a preclinical study
@en
P2093
Alaa H Abuznait
Amal Kaddoumi
Charles R Ashby
Kamlesh Sodani
Rishil J Kathawala
Yue-Li Sun
Zhe-Sheng Chen
P2860
P304
P356
10.1158/1535-7163.MCT-13-0743
P577
2014-01-15T00:00:00Z